Live Breaking News & Updates on Megapharm ltd

Stay informed with the latest breaking news from Megapharm ltd on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Megapharm ltd and stay connected to the pulse of your community

Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with ...

Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with ...
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

China , Germany , United-states , United-kingdom , Israel , Hubei , Guangdong , Wuhan , Canada , Palestinian , Canadian , Jenene-thomas

Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism

– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides…

United-states , Canada , United-kingdom , Israel , Palestinian , Canadian , Jenene-thomas , Aeterna-zentaris-gmb , Richardj-ross , Klaus-paulini , Boeing , Aeterna-zentaris

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics
January 28, 2021 08:05 ET
| Source:
Aeterna Zentaris Inc
Aeterna Zentaris Inc
Montreal CANADA
- Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of
neuromyelitis optica spectrum disorder
- Initial step in growth strategy to build-out pipeline of assets
- Aeterna Zentaris to develop potential therapeutic treatment option for neuromyelitis optica spectrum disorder (“NMOSD”), an orphan indication with strong unmet medical need and significant market opportunity
CHARLESTON, S.C., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has licensed the exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific, autoimmunity modifying proteins (“AIM Biologicals”) for the potential treatment of neuromyelitis optica spectrum disorder (“NMOSD”) from the Julius-Maximilians-University Wuerzburg (the “University”).

United-states , Germany , Canada , United-kingdom , Israel , Palestinian , Canadian , Jenene-thomas , Aeterna-zentaris-gmb , Joerg-wischhusen , Klaus-paulini , Valentin-bruttel

Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

New-york , United-states , Canada , United-kingdom , Toronto , Ontario , Israel , Palestinian , Canadian , Jenene-thomas , Linkedin , Megapharm-ltd

Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million

Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

New-york , United-states , Canada , United-kingdom , Toronto , Ontario , Israel , Palestinian , Canadian , Jenene-thomas , Megapharm-ltd , European-commission

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics

Article content
– Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of
neuromyelitis optica spectrum disorder
– Initial step in growth strategy to build-out pipeline of assets
– Aeterna Zentaris to develop potential therapeutic treatment option for neuromyelitis optica spectrum disorder (“NMOSD”), an orphan indication with strong unmet medical need and significant market opportunity
CHARLESTON, S.C., Jan. 28, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has licensed the exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific, autoimmunity modifying proteins (“AIM Biologicals”) for the potential treatment of neuromyelitis optica spectrum disorder (“NMOSD”) from the Julius-Maximilians-University Wuerzburg (the “University”).

United-states , Germany , Canada , United-kingdom , Israel , Palestinian , Canadian , Jenene-thomas , Aeterna-zentaris-gmb , Joerg-wischhusen , Klaus-paulini , Valentin-bruttel

Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic ...
Aeterna Zentaris IncFebruary 2, 2021 GMT
- Company secures next step to continue to build-out pipeline of assets
- University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19
- Aeterna Zentaris to evaluate the University’s coronavirus vaccine platform technology including COVID-19 under an exclusive option agreement
CHARLESTON, S.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has entered into an exclusive option agreement to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg (the “University”), one of Germany’s leading research and teaching universities. The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine.

Wuhan , Hubei , China , Germany , United-states , United-kingdom , Israel , Guangdong , Canada , Palestinian , Canadian , German

Xeris Pharmaceuticals Announces Distribution Agreement With Megapharm Ltd. to Commercialize Gvoke® in Israel and the Palestinian Authority

Published: Dec 22, 2020
CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc.,(Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has entered into an exclusive distribution agreement with Megapharm Ltd. (“Megapharm”), a leading Israel-based pharmaceutical company, for the commercialization in Israel and the Palestinian Authority of Xeris’ Gvoke® (glucagon injection) for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above. Gvoke® is the world’s first and only ready-to-use liquid glucagon.
Under the terms of the agreement, Megapharm will be responsible for registration and marketing of Gvoke® in Israel and the Palestinian Authority, as well as named patient services supply, and Xeris will be responsible for manufacturing, product supply, quality assurance and control, regulatory support, and maintenance of IP. Gvoke® is expected to be available in Israel in 2022. Gvoke® will also be available in Israel prior to registration on a named patient basis starting in early 2021.

Japan , United-states , Israel , Chicago , Illinois , Japanese , Israeli , American , Palestinian , Miron-drucker , Paulr-edick , Exchange-commission